Bitcoin Price Eyes Rally to $100,000 as ETF Inflows Surge, Technicals Align
Bitcoin surged to a multi-month high of $87,270 on Monday before pulling back below $84,000 as US bond yields climbed.
Crypto · News reference
Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Fall as Trump Launches ‘Operation Economic Fury’ on Iran— BULL, WMT, MRK Stock in Focus (UPDATED)
Editor’s note: The ETFs data was updated and economic data was added U.S. stock futures were lower on Thursday, as the Dow Jones, S&P 500 and Nasdaq 100 indices fell, following Wednesday’s higher
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Brian Armstrong Once Said There is a 'Foundation of Things' Everyone Must Lay Before Doing Bunch of Other Stuff — Here's What the Coinbase CEO Does
Coinbase Global Inc. CEO Brian Armstrong once suggested that people prioritize their personal health and well-being before focusing on anything else.
XRP Could Overtake Bitcoin, Analyst Says: 'Life Happens Fast'
XRP could overtake Bitcoin if trillions moving onto the XRP Ledger create sustained demand for the token, analyst Rob Cunningham says.
Why Bitcoin Hit $86,000 Despite Fed Rate Hikes - VanEck's Sigel, Former CFTC Chair Weigh In
Bitcoin’s rally reflects seller exhaustion, improving liquidity and demand for a scarce hedge against debt and currency debasement, despite higher rates.
Why Is Webull Stock Falling on Thursday?
Webull Corp. (NASDAQ: BULL) stock falls on Thursday following regulatory disclosures showing insider sales by company executives under pre-arranged trading plans.
Merck, Daiichi Sankyo Voluntarily Withdraw Biologics License Application Approval In U.S. For Ifinatamab Deruxtecan To Treat Small Cell Lung Cancer After Discussions With FDA
The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan